Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.17
AKRX's Cash to Debt is ranked lower than
90% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. AKRX: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
AKRX' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.23 Max: No Debt
Current: 0.17
Equity to Asset 0.36
AKRX's Equity to Asset is ranked lower than
83% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. AKRX: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
AKRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.53 Max: 0.91
Current: 0.36
0.1
0.91
Interest Coverage 5.08
AKRX's Interest Coverage is ranked lower than
74% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. AKRX: 5.08 )
Ranked among companies with meaningful Interest Coverage only.
AKRX' s Interest Coverage Range Over the Past 10 Years
Min: 2.71  Med: 7.57 Max: 9999.99
Current: 5.08
2.71
9999.99
F-Score: 5
Z-Score: 2.86
M-Score: -2.19
WACC vs ROIC
11.50%
14.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.72
AKRX's Operating margin (%) is ranked higher than
90% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. AKRX: 28.72 )
Ranked among companies with meaningful Operating margin (%) only.
AKRX' s Operating margin (%) Range Over the Past 10 Years
Min: -37.46  Med: 14.68 Max: 29.91
Current: 28.72
-37.46
29.91
Net-margin (%) 13.45
AKRX's Net-margin (%) is ranked higher than
75% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. AKRX: 13.45 )
Ranked among companies with meaningful Net-margin (%) only.
AKRX' s Net-margin (%) Range Over the Past 10 Years
Min: -36.24  Med: 9.89 Max: 31.41
Current: 13.45
-36.24
31.41
ROE (%) 34.46
AKRX's ROE (%) is ranked higher than
94% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. AKRX: 34.46 )
Ranked among companies with meaningful ROE (%) only.
AKRX' s ROE (%) Range Over the Past 10 Years
Min: -50.57  Med: 15.58 Max: 35.12
Current: 34.46
-50.57
35.12
ROA (%) 8.20
AKRX's ROA (%) is ranked higher than
71% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. AKRX: 8.20 )
Ranked among companies with meaningful ROA (%) only.
AKRX' s ROA (%) Range Over the Past 10 Years
Min: -33.5  Med: 5.29 Max: 24.27
Current: 8.2
-33.5
24.27
ROC (Joel Greenblatt) (%) 82.47
AKRX's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. AKRX: 82.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -41.62  Med: 45.27 Max: 73.47
Current: 82.47
-41.62
73.47
Revenue Growth (3Y)(%) 50.10
AKRX's Revenue Growth (3Y)(%) is ranked higher than
95% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AKRX: 50.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AKRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.1  Med: 3.70 Max: 54
Current: 50.1
-37.1
54
EBITDA Growth (3Y)(%) 61.60
AKRX's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AKRX: 61.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AKRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.3  Med: 37.00 Max: 128.9
Current: 61.6
-63.3
128.9
EPS Growth (3Y)(%) 56.20
AKRX's EPS Growth (3Y)(%) is ranked higher than
91% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. AKRX: 56.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AKRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.4  Med: 1.50 Max: 96.9
Current: 56.2
-50.4
96.9
» AKRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AKRX Guru Trades in Q2 2015

Steven Cohen 485,000 sh (+147.20%)
Mario Gabelli 23,100 sh (+77.69%)
Paul Tudor Jones 32,050 sh (+14.56%)
Murray Stahl 19,285 sh (+8.83%)
George Soros Sold Out
Joel Greenblatt Sold Out
Columbia Wanger 3,422,713 sh (-18.69%)
Louis Moore Bacon 7,400 sh (-89.43%)
» More
Q3 2015

AKRX Guru Trades in Q3 2015

Jim Simons 274,120 sh (New)
Mario Gabelli 29,500 sh (+27.71%)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 18,866 sh (-2.17%)
Columbia Wanger 3,316,265 sh (-3.11%)
Steven Cohen 374,100 sh (-22.87%)
» More
Q4 2015

AKRX Guru Trades in Q4 2015

John Paulson 2,879,138 sh (New)
George Soros 20,100 sh (New)
Andreas Halvorsen 1,841,346 sh (New)
Steven Cohen 427,865 sh (+14.37%)
Mario Gabelli 31,100 sh (+5.42%)
Jim Simons Sold Out
Murray Stahl 16,548 sh (-12.29%)
Columbia Wanger 2,735,646 sh (-17.51%)
» More
Q1 2016

AKRX Guru Trades in Q1 2016

John Paulson 9,318,600 sh (+223.66%)
Murray Stahl 27,192 sh (+64.32%)
Mario Gabelli 46,300 sh (+48.87%)
Andreas Halvorsen 2,081,398 sh (+13.04%)
Steven Cohen Sold Out
George Soros Sold Out
Columbia Wanger 2,096,707 sh (-23.36%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OCSE:LUN, TSE:4581, BOM:524804, NYSE:MNK, SHSE:600196, OSTO:MEDA A » details
Traded in other countries:FDA.Germany,
Akorn Inc manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.

Akorn Inc is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. The Company manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals. In addition, it has markets and distributes vaccines purchased from outside sources. It operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, and in Paonta Sahib, Himachal Pradesh, India. It also operates a Research and Development center in Vernon Hills, Illinois and a distribution warehouse in Gurnee, Illinois. Its three operating segments are: ophthalmic; hospital drugs & injectables; contract services. Ophthalmic Segment: It markets a full line of diagnostic and therapeutic ophthalmic pharmaceutical products. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others. Therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers, include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers. Hospital Drugs & Injectables Segment - it markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia, and other selected pharmaceutical products. These products are predominately sold to hospitals through the wholesale distribution channel. The Companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company targets products with limited competition due to difficulty in manufacturing and/or the products market size. Contract Services Segment: It manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The Company is competitors for hospital drugs & injectables segment include both generic and name brand companies such as Hospira, Inc., Teva Pharmaceutical Industries, Pfizer, Sagent Pharmaceuticals, Novartis, Fresenius-Kabi, Daiichi Sankyo, and Hikma. For ophthalmic segment its competitors include, Allergan Pharmaceuticals, Inc., Novartis, Valeant Pharmaceuticals International, Inc., Apotex and Sun Pharmaceuticals, among others.

Top Ranked Articles about Akorn Inc

John Paulson Increases Bet on Health Care for 7th Quarter Hedge fund manager increased sector for seventh consecutive quarter to more than half of long portfolio
As 13F filings rolled in this week, the most notable revelation of John Paulson (Trades, Portfolio)’s was his reduction of his SPDR Gold Trust (GLD) stake, a mainstay of his portfolio for years, at a significant loss. Paulson, the head of hedge fund Paulson & Co., in his next most prominent move increased his holding of health care stocks for the seventh consecutive quarter. The sector made up more than 57% of his long portfolio, compared to 48.3% the previous quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 39.48
AKRX's P/E(ttm) is ranked lower than
67% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. AKRX: 39.48 )
Ranked among companies with meaningful P/E(ttm) only.
AKRX' s P/E(ttm) Range Over the Past 10 Years
Min: 13.23  Med: 47.81 Max: 498.24
Current: 39.48
13.23
498.24
Forward P/E 12.90
AKRX's Forward P/E is ranked higher than
57% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. AKRX: 12.90 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 40.52
AKRX's PE(NRI) is ranked lower than
67% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. AKRX: 40.52 )
Ranked among companies with meaningful PE(NRI) only.
AKRX' s PE(NRI) Range Over the Past 10 Years
Min: 13.17  Med: 48.47 Max: 448.42
Current: 40.52
13.17
448.42
P/B 5.42
AKRX's P/B is ranked lower than
77% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. AKRX: 5.42 )
Ranked among companies with meaningful P/B only.
AKRX' s P/B Range Over the Past 10 Years
Min: 1.42  Med: 6.60 Max: 41.45
Current: 5.42
1.42
41.45
P/S 14.24
AKRX's P/S is ranked lower than
86% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. AKRX: 14.24 )
Ranked among companies with meaningful P/S only.
AKRX' s P/S Range Over the Past 10 Years
Min: 0.75  Med: 6.47 Max: 20.66
Current: 14.24
0.75
20.66
POCF 422.27
AKRX's POCF is ranked lower than
99% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. AKRX: 422.27 )
Ranked among companies with meaningful POCF only.
AKRX' s POCF Range Over the Past 10 Years
Min: 27.11  Med: 53.88 Max: 430.02
Current: 422.27
27.11
430.02
EV-to-EBIT 49.61
AKRX's EV-to-EBIT is ranked lower than
85% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. AKRX: 49.61 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -4983.2  Med: 18.60 Max: 213.1
Current: 49.61
-4983.2
213.1
EV-to-EBITDA 39.52
AKRX's EV-to-EBITDA is ranked lower than
81% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. AKRX: 39.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -506.9  Med: 19.40 Max: 2955.7
Current: 39.52
-506.9
2955.7
PEG 1.73
AKRX's PEG is ranked higher than
52% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. AKRX: 1.73 )
Ranked among companies with meaningful PEG only.
AKRX' s PEG Range Over the Past 10 Years
Min: 0.08  Med: 0.13 Max: 2.55
Current: 1.73
0.08
2.55
Shiller P/E 240.88
AKRX's Shiller P/E is ranked lower than
96% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. AKRX: 240.88 )
Ranked among companies with meaningful Shiller P/E only.
AKRX' s Shiller P/E Range Over the Past 10 Years
Min: 145  Med: 615.50 Max: 2690.5
Current: 240.88
145
2690.5
Current Ratio 2.72
AKRX's Current Ratio is ranked higher than
56% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. AKRX: 2.72 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.24 Max: 9.96
Current: 2.72
0.21
9.96
Quick Ratio 1.74
AKRX's Quick Ratio is ranked lower than
53% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. AKRX: 1.74 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.10 Max: 8.49
Current: 1.74
0.02
8.49
Days Inventory 111.59
AKRX's Days Inventory is ranked higher than
52% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. AKRX: 111.59 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s Days Inventory Range Over the Past 10 Years
Min: 90.54  Med: 142.57 Max: 188.37
Current: 111.59
90.54
188.37
Days Sales Outstanding 91.68
AKRX's Days Sales Outstanding is ranked lower than
62% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. AKRX: 91.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.49  Med: 51.71 Max: 115.42
Current: 91.68
24.49
115.42
Days Payable 55.84
AKRX's Days Payable is ranked lower than
62% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. AKRX: 55.84 )
Ranked among companies with meaningful Days Payable only.
AKRX' s Days Payable Range Over the Past 10 Years
Min: 19.92  Med: 52.74 Max: 123.76
Current: 55.84
19.92
123.76

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 5.41
AKRX's Price/Projected FCF is ranked lower than
69% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. AKRX: 5.41 )
Ranked among companies with meaningful Price/Projected FCF only.
AKRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.19  Med: 13.90 Max: 749
Current: 5.41
4.19
749
Price/Median PS Value 2.20
AKRX's Price/Median PS Value is ranked lower than
83% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. AKRX: 2.20 )
Ranked among companies with meaningful Price/Median PS Value only.
AKRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.34 Max: 3.18
Current: 2.2
0.03
3.18
Price/Peter Lynch Fair Value 3.68
AKRX's Price/Peter Lynch Fair Value is ranked lower than
86% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. AKRX: 3.68 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AKRX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.47  Med: 1.43 Max: 4.97
Current: 3.68
0.47
4.97
Earnings Yield (Greenblatt) (%) 2.03
AKRX's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. AKRX: 2.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 3.30 Max: 7.3
Current: 2.03
0.5
7.3
Forward Rate of Return (Yacktman) (%) 36.89
AKRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
92% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. AKRX: 36.89 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AKRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.5  Med: -1.50 Max: 951.9
Current: 36.89
-15.5
951.9

More Statistics

Revenue (TTM) (Mil) $685.5
EPS (TTM) $ 0.77
Beta1.75
Short Percentage of Float11.91%
52-Week Range $17.57 - 48.53
Shares Outstanding (Mil)119.43

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,077 1,178 1,289
EPS ($) 2.16 2.40 2.73
EPS without NRI ($) 2.16 2.40 2.73
EPS Growth Rate
(3Y to 5Y Estimate)
10.86%
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Analysts Disagree Over Significance of Akorn, Inc’s Financial Errors Apr 28 2015 
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Weekly CFO Sells Highlight: AN, CATM, AKRX, NNN, FTNT Aug 28 2011 
Akorn Inc. (AKRX) CFO Timothy A Dick buys 3,900 Shares Aug 16 2010 
Akorn Inc. Reports Operating Results (10-Q) May 10 2010 
Akorn Inc. Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
AKORN INC Financials May 24 2016
AKORN INC Files SEC form 8-K, Regulation FD Disclosure May 20 2016
Billionaire John Paulson Boosts Stakes in Endo Pharmaceuticals, Akorn; Plus Top Three New Positions May 20 2016
[$$] Generics Stocks Deserve More Love May 19 2016
Akorn (AKRX) Shares March Higher, Can It Continue? May 19 2016
Akorn Rebounds Further As Q1 Meets Views, Big Investor Ups Stake May 17 2016
Edited Transcript of AKRX earnings conference call or presentation 17-May-16 2:00pm GMT May 17 2016
Akorn Inc Earnings Call scheduled for 10:00 am ET today May 17 2016
Paulson Triples Stakes in Endo, Akorn as Other Hedge Funds Sell May 16 2016
AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 16 2016
AKORN INC Files SEC form 10-Q, Quarterly Report May 16 2016
Akorn Provides First Quarter 2016 Results May 16 2016
Akorn meets 1Q profit forecasts May 16 2016
Akorn meets 1Q profit forecasts May 16 2016
Akorn Provides First Quarter 2016 Results May 16 2016
5 Stocks Set to Soar on Bullish Earnings May 16 2016
XBI and IHI Rose despite the Biotechnology Sector’s Sluggish Week May 16 2016
Akorn, Inc. :AKRX-US: Earnings Analysis: 2015 By the Numbers May 16 2016
Q1 2016 Akorn Inc Earnings Release - After Market Close May 16 2016
Edited Transcript of AKRX earnings conference call or presentation 10-May-16 2:00pm GMT May 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)